Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Dominik Paul Modest

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6853-0599; OpenAlex author ID A5055766851. Sources: OpenAlex.

Their work

Papers
12
Trials
0
Grants
0
Labs led
0
Collaborators
45
Papers, trials and grants by year

2013: 2 papers · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: none · 2020: none · 2021: 3 papers · 2022: none · 2023: none · 2024: 2 papers

Papers 12

  1. Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116… Co-author DOI 10.1007/s00432-024-05827-x↗
  2. Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pan… Co-author DOI 10.1016/s2468-1253(24)00197-3↗
  3. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma -… Co-author DOI 10.1016/j.ejca.2021.03.036↗
  4. Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. Co-author DOI 10.3389/fonc.2021.670396↗
  5. Nerve Fibers in the Tumor Microenvironment Are Co-Localized with Lymphoid Aggregates in Pancreatic Cancer. Co-author DOI 10.3390/jcm10030490↗
  6. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Co-author DOI 10.1080/2162402x.2017.1310358↗
  7. Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational resea… Co-author DOI 10.1186/s12885-017-3376-4↗
  8. Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2016.03.016↗
  9. Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3. Co-author DOI 10.1007/s13277-014-2885-x↗
  10. Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis fr… Co-author DOI 10.3109/0284186x.2015.1034877↗
  11. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analys… Co-author DOI 10.1007/s00432-012-1371-3↗
  12. KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s00535-013-0767-4↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Volker Heinemann · 9 shared papers, 2013–2024 · strength 0.66
  2. Helmut Oettle · 4 shared papers, 2021–2024 · strength 0.57
  3. Stefan Hubert Boeck · 8 shared papers, 2013–2024 · strength 0.49
  4. Annika Kurreck · 3 shared papers, 2021–2024 · strength 0.40
  5. Stephan Krüger · 6 shared papers, 2015–2021 · strength 0.38
  6. Volker Kunzmann · 2 shared papers, 2024 · strength 0.33
  7. Oliver Waidmann · 2 shared papers, 2024 · strength 0.33
  8. Michael Haas · 7 shared papers, 2013–2017 · strength 0.33
  9. Steffen Ormanns · 5 shared papers, 2013–2017 · strength 0.25
  10. Marcus Bahra · 2 shared papers, 2021 · strength 0.24
  11. Jana Käthe Striefler · 2 shared papers, 2021 · strength 0.24
  12. Marianne Sinn · 2 shared papers, 2021 · strength 0.24
  13. Uwe Pelzer · 2 shared papers, 2021 · strength 0.24
  14. Hanno B. Riess · 2 shared papers, 2021 · strength 0.24
  15. Michael Geißler · 2 shared papers, 2015–2024 · strength 0.20
  16. Frank Kullmann · 2 shared papers, 2013–2024 · strength 0.20
  17. Larissa Henze · 1 shared paper, 2024 · strength 0.16
  18. Thomas Jens Ettrich · 1 shared paper, 2024 · strength 0.16
  19. Maximilian Reichert · 1 shared paper, 2024 · strength 0.16
  20. Klara Dorman · 1 shared paper, 2024 · strength 0.16
  21. Anke Reinacher‐Schick · 1 shared paper, 2024 · strength 0.16
  22. Patrick Michl · 1 shared paper, 2024 · strength 0.16
  23. Stefan Holdenrieder · 3 shared papers, 2013–2017 · strength 0.14
  24. Bruno Valentin Sinn · 1 shared paper, 2021 · strength 0.11
  25. Philipp Lohneis · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.